Quick Answer
Anebulo Pharmaceuticals, Inc. reported Net Income of -$8.48 million for fiscal year 2025.
Anebulo Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$8.48M | -3.5% |
| 2024 | -$8.20M | +30.1% |
| 2023 | -$11.73M | -71.9% |
| 2022 | -$6.83M | +77.4% |
| 2021 | -$30.25M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$2.00M | +18.8% | +7.4% |
| September 30, 2025 | -$2.16M | +1.9% | -28.8% |
| March 31, 2025 | -$1.68M | -1.4% | +31.9% |
| December 31, 2024 | -$2.46M | +9.4% | -11.9% |
| September 30, 2024 | -$2.20M | +11.3% | -33.1% |
| March 31, 2024 | -$1.65M | +40.9% | +39.1% |
| December 31, 2023 | -$2.72M | +29.0% | -9.5% |
| September 30, 2023 | -$2.48M | +5.0% | +11.3% |
- Anebulo Pharmaceuticals, Inc. showed a decrease of -3.5% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, Anebulo Pharmaceuticals, Inc.’s net income has grown by 72.0% (from -$30.25 million to -$8.48 million).
- The most recent figure is from Anebulo Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: